Your browser doesn't support javascript.
loading
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting.
Park, Julie R; Villablanca, Judith G; Hero, Barbara; Kushner, Brian H; Wheatley, Keith; Beiske, Klaus H; Ladenstein, Ruth L; Baruchel, Sylvain; Macy, Margaret E; Moreno, Lucas; Seibel, Nita L; Pearson, Andrew D; Matthay, Katherine K; Valteau-Couanet, Dominique.
Afiliación
  • Park JR; Seattle Children's Hospital, Seattle, Washington, USA.
  • Villablanca JG; Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA.
  • Hero B; Children's Hospital Los Angeles, Los Angeles, California, USA.
  • Kushner BH; Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Wheatley K; Children's Hospital, University of Cologne, Cologne, Germany.
  • Beiske KH; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Ladenstein RL; University of Birmingham, Birmingham, UK.
  • Baruchel S; Department of Pathology, Oslo University Hospital, Oslo, Norway.
  • Macy ME; Children's Cancer Research Institute, St Anna Children's Hospital, Vienna, Austria.
  • Moreno L; Hospital for Sick Children, Toronto, Ontario, Canada.
  • Seibel NL; Department of Pediatrics, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, Colorado, USA.
  • Pearson AD; Division of Paediatric Haematology and Oncology, Vall d'Hebron Hospital Universitari, Barcelona, Spain.
  • Matthay KK; Clinical Investigations Branch, National Cancer Institute, Bethesda, Maryland, USA.
  • Valteau-Couanet D; Division of Cancer Therapeutics, Institute of Cancer Research, Sutton, UK.
Cancer ; 128(21): 3775-3783, 2022 11 01.
Article en En | MEDLINE | ID: mdl-36101004
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: 3-Yodobencilguanidina / Neuroblastoma Tipo de estudio: Guideline / Prognostic_studies Límite: Child / Humans País/Región como asunto: America do norte Idioma: En Revista: Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: 3-Yodobencilguanidina / Neuroblastoma Tipo de estudio: Guideline / Prognostic_studies Límite: Child / Humans País/Región como asunto: America do norte Idioma: En Revista: Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos